Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
On December 31, 2025, Corcept announced in a press release that the “U.S. Food and Drug Administration (FDA or the Agency) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.” The Company stated in the press release that “the Agency concluded it could not arrive at a favorable benefit-risk assessment for relacorilant without Corcept providing additional evidence of effectiveness.”
Following this news, Corcept’s stock price fell more than 50%, to a closing price of $34.80 per share on December 31, 2025.
If you have purchased Corcept common stock, and have suffered a loss, realized or unrealized, and you wish to discuss this investigation, please contact attorney Mandeep S. Minhas at (888) 398-9312 or at [email protected].